Code Compliance Promotion Committee

Priority Issues

Supporting member companies in promoting compliance
Promotion of appropriate information disclosure based on transparency guidelines
Response to the "Guidelines for the Provision of Marketing Information on Ethical Drugs
Collaboration, information collection, dissemination, and feedback with the government and related domestic and international organizations such as the Federation of Pharmaceutical Manufacturers' Associations of Japan (JFPMA), the Fair Trade Council of the Ethical Drug Manufacturers and Distributors Association (JFTC), and the International Federation of Pharmaceutical Manufacturers' Associations (IFPMA)
Revision of the "Pharmaceutical Association of Japan Code of Practice" and dissemination to member companies

Support member companies in promoting compliance by conducting compliance surveys, etc. as necessary, identifying issues and considering measures, holding regular training sessions, etc. (Code/Compliance Management Managers and Practice Managers Meetings, etc.), implementing measures during the Code Understanding Promotion Month, and sending out notices as necessary. Support member companies in promoting compliance by holding regular training sessions, etc. (Code/Compliance Manager meetings, etc.), implementing measures during the code understanding promotion month, and sending notices as necessary.
Respond promptly and appropriately to inquiries, complaints, etc. related to the Pharmaceutical Manufacturers Association Code of Practice, and if necessary, take measures to request voluntary improvements from member companies that have violated the Code, and share examples of such measures with member companies to prevent recurrence.

Support activities to increase the transparency of the relationship between member companies and medical institutions, etc., and promote information disclosure in accordance with the Transparency Guidelines.
Support appropriate information disclosure by member companies by taking necessary measures such as holding training sessions (Transparency Guideline Contact Persons Meeting) and updating FAQs to further deepen member companies' understanding of the Transparency Guidelines.

As the committee in charge of guidelines for sales information provision activities for ethical drugs, the committee supports member companies' compliance with the guidelines with advice from the Advisory Council.
Confirm and review inappropriate cases in the project for monitoring sales information provision activities (commissioned by the Pharmaceutical Affairs Bureau, Ministry of Health, Labour and Welfare), and issue notices, etc. as necessary to ensure that member companies comply with the guidelines.
Collect information on relevant laws and regulations, administrative notices, etc. in a timely manner and share it with member companies.

Promote the "Consensus Framework for Ethical Collaboration in Japan" agreed upon and signed in 2018 among member companies and support the dissemination activities of relevant domestic associations in cooperation with the JFMA.
Participate in international compliance promotion activities including IFPMA Ethics & Business Integrity Committee meetings and APEC Business Ethics for SMEs Forum 2025 to gather international trends in the pharmaceutical industry and disseminate Japanese ideas. The results obtained through these promotion activities will be fed back to the Committee and reflected in its initiatives as necessary.
Collect information on relevant laws and regulations, administrative notices, etc. in a timely manner and share it with member companies.

Revise the "Pharmaceutical Manufacturers Association Code of Practice" and disseminate the revised contents to member companies, and request member companies to reflect the revised contents in their own codes.